Seegnal Inc. Receives Gold Mark from the Standards Institution of Israel, Advancing Commercialization Readiness

Seegnal Inc. Receives Gold Mark from the Standards Institution of Israel, Advancing Commercialization Readiness

Triple ISO Certification Recognition Positions Company as a Standard-Bearer in Clinical Decision Support Quality Infrastructure

Seegnal Inc. (TSXV: SEGN) ("Seegnal" or the "Company"), a global leader in clinical decision support solutions applying patient-centric medication safety standards, today announced that Seegnal eHealth Ltd., its Israeli operating subsidiary, has been granted the prestigious Gold Mark by the Standards Institution of Israel, a high institutional quality distinction awarded to organizations that have embedded a culture of excellence across their management systems, processes, and product lifecycle. The Gold Mark certification further solidifies Seegnal's commercialization-readiness and its standing as an enterprise-grade platform trusted by leading healthcare systems.

A Landmark Recognition in Quality Leadership
The Gold Mark is conferred exclusively upon organizations that have adopted quality and excellence as a foundational organizational ethos, not merely as a compliance exercise, and that simultaneously hold three or more quality certification marks attesting to the alignment of their management systems, processes, and products with Israeli and international standards. It represents the intersection of institutional rigor, operational discipline, and an unwavering commitment to safety and performance.

Seegnal eHealth Ltd. received the Gold Mark in recognition of holding all three of the following certification marks, each issued by the Standards Institution of Israel:

  • ISO 13485:2016: Medical Devices Quality Management Systems, certifying that Seegnal's quality management processes meet the most demanding international standards applicable to medical device manufacturers and suppliers;
  • ISO 27799: Information Security Management in Health, confirming that Seegnal's data governance and information security architecture conform to sector-specific requirements for the handling of sensitive health data; and
  • ISO 27001:2022: Information Security Management Systems (ISMS), attesting to a certified and independently audited information security management framework across the organization.

The Gold Mark certificate for 2026 was signed by Dr. Gilad Golub, CEO of the Standards Institution of Israel, and Avital Weinberg, VP of the Quality & Certification Division.

About Seegnal Inc.
Seegnal Inc. (TSXV: SEGN) is a global leader in clinical decision support, applying patient-centric medication safety standards to improve outcomes across healthcare systems. Seegnal's proprietary platform is deployed at leading hospital networks and provides real-time, point-of-care medication safety intelligence. For more information, visit www.seegnal.com.

Contact Information
Elad Bibi-Aviv
Chief Executive Officer
+1 (929) 248 4652
Arx Investor Relations
North American Equities Desk
seegnal@arxhq.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

The securities have not been and will not be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirement. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Source

SEGN:CA
The Conversation (0)
Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway.

Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway.

(TheNewswire) Retatrutide and amycretin are being investigated for compatibility with Lexaria's proprietary DehydraTECH™ Kelowna, British Columbia - June 9, 2026 TheNewswire - Lexaria Bioscience Corp. (NASDAQ: LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery... Keep Reading...
Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway

Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway

Retatrutide and amycretin are being investigated for compatibility with Lexaria's proprietary DehydraTECH™ KELOWNA, BC / ACCESS Newswire / June 9, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, announces that dosing... Keep Reading...
Doctor holds tablet displaying digital human body with health data, overlaid with medical icons.

Immunotherapy Innovations: Increasing Survival in Metastatic Breast Cancer

Metastatic breast cancer (MBC) remains incurable, with approximately only one-third of diagnosed women meeting the five year survival rate.Subtypes like triple-negative breast cancer (TNBC) or heavily pretreated hormone receptor-positive disease often come with more treatment challenges, leading... Keep Reading...
Lexaria Attending the BIO International Convention, as Part of a Broader Business Development Program

Lexaria Attending the BIO International Convention, as Part of a Broader Business Development Program

KELOWNA, BC / ACCESS Newswire / June 3, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, announces that it is attending the BIO International Convention ("BIO") from June 22-25 in San Diego, CA. Lexaria's attendance... Keep Reading...
Collage with hands holding shiny DNA molecule on blue background.

5 Biggest Biotechnology ETFs in 2026

The biotech sector has made significant strides in recent years, and the market's volatility can increase the appeal of biotech ETFs. Even with a good understanding of the system, no one can predict which treatment, device or therapy will give the biggest return, making biotech exchange-traded... Keep Reading...
Doctor holding stethoscope over digital document interface

Beyond the Lab: Top-Tier Clinical Validation in Biotech Investing

Nature Medicine’s “Eleven Clinical Trials That Will Shape Medicine in 2026” highlights studies poised to influence patient care. Among the oncology selections, BriaCell Therapeutics' (TSX:BCT,NASDAQ:BCTX) pivotal Phase 3 trial of Bria-IMT™ stands out as a rare entry. This feature underscores the... Keep Reading...

Interactive Chart

Latest Press Releases

Related News